Montreal Neurological Institute and Hospital

Montreal, Quebec QC H3A 2B4

3 studies enrolling now · 51 studies all time

What they study most

ALS, Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Anaplastic Astrocytoma, Autoimmune Diseases of the Nervous System, Brain Atrophy, Brain Cancer, Disease Progression, Drug Resistant Epilepsy, Epilepsy, Facioscapulohumeral Muscular Dystrophy (FSHD), Frontotemporal Dementia

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — Recruiting now
• A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Recruiting now
• A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity — Recruiting now
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• Safety Study of Oral Edaravone Administered in Subjects With ALS — Completed
• Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS — Stopped early
• Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) — Completed
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis — Running, not enrolling
• Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS — Running, not enrolling
• Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) — Stopped early
• Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme — Running, not enrolling
• Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE) — Stopped early
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease — Completed
• A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis — Stopped early
• Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis — Completed
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) — Stopped early
• Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System. — Completed
• Spinraza in Adult Spinal Muscular Atrophy — Running, not enrolling
• SAHaRA: A Randomized Controlled Trial — Completed
• A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) — Stopped early
• Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) — Completed
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis — Completed
• A Study of RVT-1401 in Myasthenia Gravis (MG) Patients — Completed
• Intranasal Oxytocin for Frontotemporal Dementia — Status unconfirmed
• A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy — Completed
• Arimoclomol in Amyotropic Lateral Sclerosis — Completed
• An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) — Completed
• Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension — Stopped early
• An Efficacy and Safety Study of Ravulizumab in ALS Participants — Stopped early
• Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke — Completed
• Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure — Completed
• Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis — Completed
• Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS — Completed
• Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients — Status unconfirmed
• A Study for Patients Who Completed VITALITY-ALS (CY 4031) — Completed
• Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures — Completed
• Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation — Stopped early
• Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations — Stopped early
• A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) — Completed
• Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year — Completed
• A Study of CK-2127107 in Patients With Spinal Muscular Atrophy — Completed
• IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis — Completed
• Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage — Stopped early
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma — Completed
• Antihypertensive Treatment of Acute Cerebral Hemorrhage-II — Stopped early
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
• Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis — Completed
• MAPS Trial: Matrix And Platinum Science — Completed